New cell therapy trial offers hope for lymphoma patients out of options

NCT ID NCT07453446

Recruiting now Disease control Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new type of personalized cell therapy called CD30-targeted CAR-T for adults with lymphoma that has come back or not responded to standard treatments. The main goals are to see if the treatment is safe and if it can shrink tumors. Researchers will track side effects and how well patients respond over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hebei Yanda Lu Daopei Hospital
RECRUITING

Sanhe, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY LYMPHOMA